Kromek Group PLC

Issue of Equity and Total Voting Rights

RNS Number : 0515O
Kromek Group PLC
04 February 2021

4 February 2021


Kromek Group plc

("Kromek" or the "Company")


Issue of Equity and Total Voting Rights


Kromek Group plc, a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces the issuance of 338,000 new ordinary shares (the "Options") in the Company as a result of the exercise of employee options during the period from 1 February 2019 to 17 July 2020. Following the exercise of the Options, the Company's issued share capital consists of 344,897,089 ordinary shares of 1p each. This figure (344,897,089) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Application has been made for a total of 2,008,000 new ordinary shares to be admitted to trading on AIM ("Admission"). This number is made up of the Options and a further 1,670,000 new ordinary shares resulting from the historic exercise of options that were not previously admitted to trading. It is expected that Admission will occur on 10 February 2021. Following Admission, the Company will have 344,897,089 ordinary shares in issue and admitted to trading on AIM.


For further information, please contact:


Kromek Group plc


Arnab Basu, CEO

Paul Farquhar, CFO


+44 (0)1740 626 060

Cenkos Securities plc (Nominated Adviser and Broker)


Max Hartley (NOMAD)

Julian Morse (Sales)


+44 (0)20 7397 8900

Luther Pendragon Ltd (PR)


Harry Chathli

Claire Norbury

Joe Quinlan

+44 (0)20 7618 9100


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.